Beam Therapeutics Inc
NASDAQ:BEAM

Watchlist Manager
Beam Therapeutics Inc Logo
Beam Therapeutics Inc
NASDAQ:BEAM
Watchlist
Price: 27.46 USD -0.18% Market Closed
Market Cap: 2.8B USD

Wall Street
Price Targets

BEAM Price Targets Summary
Beam Therapeutics Inc

Wall Street analysts forecast BEAM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BEAM is 46.24 USD with a low forecast of 21.21 USD and a high forecast of 84 USD.

Lowest
Price Target
21.21 USD
23% Downside
Average
Price Target
46.24 USD
68% Upside
Highest
Price Target
84 USD
206% Upside
Beam Therapeutics Inc Competitors:
Price Targets
QURE
Uniqure NV
192% Upside
XGN
Exagen Inc
121% Upside
MNKD
MannKind Corp
59% Upside
6855
Ascentage Pharma Group International
78% Upside
688266
Suzhou Zelgen Biopharmaceuticals Co Ltd
35% Upside
NRIX
Nurix Therapeutics Inc
45% Upside
REGN
Regeneron Pharmaceuticals Inc
8% Upside
2162
KeyMed Biosciences Inc
56% Upside

Revenue
Forecast

Revenue Estimate
Beam Therapeutics Inc

The compound annual growth rate of Beam Therapeutics Inc's revenue for the next 3 years is -1%.

N/A
Past Growth
-1%
Estimated Growth
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Beam Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Beam Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BEAM's stock price target?
Price Target
46.24 USD

According to Wall Street analysts, the average 1-year price target for BEAM is 46.24 USD with a low forecast of 21.21 USD and a high forecast of 84 USD.

What is Beam Therapeutics Inc's Revenue forecast?
Projected CAGR
-1%

The compound annual growth rate of Beam Therapeutics Inc's revenue for the next 3 years is -1%.

Back to Top